BOCOUTURE® 50u (XEOMIN®) 2 vials

BOCOUTURE® 50u, also branded as XEOMIN®, is a botulinum neurotoxin type A indicated for aesthetic and therapeutic purposes. It is a purified neurotoxin without accessory proteins, reducing the risk of antibody formation. Each vial contains 50 units of incobotulinumtoxinA and is used for the treatment of glabellar lines, blepharospasm, cervical dystonia, and upper limb spasticity in adult patients.

The product works by inhibiting acetylcholine release, temporarily preventing muscle contractions. It is administered via intramuscular injection after reconstitution with preservative-free 0.9% sodium chloride. This version is often preferred for smaller treatment areas or initial dosing, as each box contains two single-use 50u vials.

BOCOUTURE® is reconstituted before injection and used within 24 hours, administered by professionals trained in neurotoxin techniques.

Key Features:

• Precise dosing options for low-volume indications
  
• No complexing proteins, minimizing immunogenicity
  

Reconstitution Guidelines:

• Dilute with 0.25–2.5 mL saline
  
• Produces concentrations ranging from 1–20 Units per 0.1 mL
  

Typical Use Cases:

• Glabellar lines: 20 Units total, 5 injections (4U each)
  
• Blepharospasm: ~33 Units per eye (max 50 Units per eye)
  
• Cervical dystonia: 120 Units initial dose (can combine vials)
  
• Upper limb spasticity: up to 400 Units total (multi-vial administration)

Indications:

• Glabellar lines (moderate to severe) in adults
  
• Blepharospasm in previously Botox-treated patients
  
• Cervical dystonia in botulinum toxin–naïve or experienced adults
  
• Upper limb spasticity in adults
  

Contraindications:

• Hypersensitivity to botulinum toxin A, human albumin, or sucrose
  
• Active infection at injection sites
  

Common Side Effects:

• Glabellar lines: headache, eyelid edema, brow ptosis
  
• Cervical dystonia: dysphagia, neck pain, muscle weakness
  
• Blepharospasm: dry eyes, visual disturbance, ptosis
  
• Upper limb spasticity: seizure, dry mouth, URT infections

Each vial contains:

• IncobotulinumtoxinA: 50 Units
  
• Human albumin: 1 mg
  
• Sucrose: 4.7 mg
  

No preservatives, no animal-derived proteins, and no complexing proteins.

Package Contents:

• Two single-dose vials, each containing 50 Units of lyophilized powder
  
• Vials are made from Type I borosilicate glass
  
• Rubber stoppers are latex-free
  
• Packaged for reconstitution with 0.9% NaCl preservative-free saline

Yes, side effects may occur and vary by treatment area and dosage.

Most Common Adverse Reactions:

• Glabellar lines: headache (5.4%), injection site pain (<1%), eyelid edema
  
• Cervical dystonia: dysphagia (13–18%), neck pain (7–15%)
  
• Blepharospasm: dry eyes (16%), ptosis (19%)
  
• Upper limb spasticity: seizure (3%), nasopharyngitis (2%)
  

Serious Risks:

• Distant spread of toxin effect: can cause dysphagia, respiratory compromise
  
• Allergic reactions: urticaria, edema, anaphylaxis (rare)

Storage Conditions:

• Unopened vials:
  
  • Room temperature: 20°C to 25°C
    
  • Refrigerated: 2°C to 8°C
    
  • Freezer: -20°C to -10°C
    
• After reconstitution:
  
  • Use within 24 hours
    
  • Store at 2°C to 8°C
    
  • Do not freeze reconstituted solution
    
• Discard unused product after 24 hours